John  Morris

John C Morris , MD

Physician

Co-Director, Comprehensive Lung Cancer Center, Associate Director, UCCI Translational Research and Director, Experimental Therapeutics

Vontz Center for Molecular Studies
3125 Eden Avenue
ML 0562
Cincinnati, Ohio 45267
Phone 513-558-2158
Fax 513-558-2124
Email john.morris2@uc.edu

Education

Medical Degree: Upstate Medical Center College of Medicine 1982

Internship: Mount Sinai Hospital 1983 (Internal Medicine)

Residency: Mount Sinai Hospital 1986 (Internal Medicine )

Fellowship: Mount Sinai Hospital 1988 (Medical Oncology)

Fellowship : Mount Sinai Hospital 1988 (Neoplastic Diseases)

Post-Doctoral Fellowship: National Institutes of Health 1999 (IPA Clinical Gene Therapy )

Bachelor's Degree: City University of New York 1978 (Biology)

Certifications

American Board of Internal Medicine (Certification Date: 09-11-1985 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-07-1989 )

Clinical Interests

Medical Oncology

Hematology and Oncology

Lung Cancer

Gallbladder Cancer

Mesothelioma

Prostate Cancer

Sarcoma

Research and Practice Interests

Lung, translational research, Phase I and II clinical trials, experimental therapeutics, immune therapy strategies, Hematology Oncology

Positions and Work Experience

11-2010 -To Present Professor, Division of Hematology/Oncology Department of Medicine, University of Cincinnati, Cincinnati, OH

07-2006 -10-2010 Staff Clinician, Metabolism Branch Center for Cancer Research, National Cancer Institute, Bethesda, MD

06-1999 -06-2006 Investigator, Metabolism Branch Center for Cancer Research, National Cancer Institute, Bethesda, MD

07-1992 -06-1999 Assistant Professor, Division of Neoplastic Diseases Department of Medicine, Mount Sinai School of Medicine, New York, New York

07-1990 -06-1992 Assistant Professor, Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York

07-1988 -06-1990 Clinical Instructor, Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York

07-1988 -06-1992 Clinical Instructor, Department of Medicine, Mount Sinai School of Medicine, New York, New York

11-2010 -To Present Attending Physician, University of Cincinnati Health/University Hospital/Barrett Cancer Center, Cincinnati, OH

11-1995 -10-2010 Staff Clinician, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD

07-1992 -06-1999 Assistant Attending, Division of Neoplastic Diseases, Mount Sinai Hopital, New York, New York

07-1990 -06-1992 Assistant Attending, Department of Neoplastic Diseases, Mount Sinai Hospital, New York, New York

07-1988 -06-1992 Clinical Attending, Department of Medicine, Mount Sinai Hospital, New York, New York

07-1988 -06-1990 Clinical Attending, Department of Neoplasstic Diseases, Mount Sinai Hospital, New York, New York

Research Support

Grant: #SRS006661 Investigators:Morris, John; Oleksowicz, Leslie 01-01-2009 -12-31-2013 National Cancer Institute Southwest Oncology Group- SWOG Role:PI $195,653.00 Active Level:Federal

Grant: #SRS006662 Investigators:Morris, John; Oleksowicz, Leslie 01-01-2009 -06-30-2014 National Cancer Institute Southwest Oncology Group- Clinical Trials Initiative Role:PI $43,479.00 Active Level:Federal

Grant: #RE11-00799 Investigators:Morris, John; Rixe, Olivier 01-01-2012 -12-31-2012 Greater Cincinnati Foundation Experimental Therapeutics Program at the University of Cincinnati Cancer Institute (UCCI) Role:PI $2,476.33 Closed Level:Private Non-Profit

Grant: #SWOG Purchase Service Agreement \ U10 CA037429 Investigators:Morris, John 06-09-2014 -05-21-2024 National Cancer Institute SWOG Purchase Service Agreement Role:PI $42,871.00 Awarded Level:Federal

Publications

Peer Reviewed Publications

Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. (01-15-2020. ) Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in.Cancer, , 126 (2 ) ,354-362 More Information

Komiya T.;Blumenthal G.M.;DeChowdhury R.;Fioravanti S.;Ballas M.S.;Morris J.;Hornyak T.J.;Wank S.;Hewitt S.M.;Morrow B.;Memmott R.M.;Rajan A.;Dennis P.A. (12-01-2019. ) A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ.Oncologist, , 24 (12 ) ,1510-e1265 More Information

Vaishampayan U.;Schöffski P.;Ravaud A.;Borel C.;Peguero J.;Chaves J.;Morris J.C.;Kotecki N.;Smakal M.;Zhou D.;Guenther S.;Bajars M.;Gulley J.L. (10-24-2019. ) Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c.Journal for ImmunoTherapy of Cancer, , 7 (1 ) , More Information

Morgensztern D.;Rose M.;Waqar S.N.;Morris J.;Ma P.C.;Reid T.;Brzezniak C.E.;Zeman K.G.;Padmanabhan A.;Hirth J.A.;I. Spira A.;Trepel J.B.;Padda S.K. (07-30-2019. ) RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc.British Journal of Cancer, , 121 (3 ) ,211-217 More Information

Rahouma M.;Karim N.A.;Baudo M.;Yahia M.;Kamel M.;Eldessouki I.;Abouarab A.;Saad I.;Elmously A.;Gray K.D.;Ghaly G.;Gaber O.;Kamal M.;A Hassan A.;Rahouma M.;D'Ascenzo F.;Morris J.;Mohamed A.;Girardi L.;Gaudino M. (05-15-2019. ) Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra.Immunotherapy, , 11 (8 ) ,725-735 More Information

Pal S.;Forero-Torres A.;Thompson J.;Morris J.;Chhabra S.;Hoimes C.;Vogelzang N.;Boyd T.;Bergerot P.;Adashek J.;Li H.;Yu X.;Gartner E.;Carret A.;Smith D. (04-01-2019. ) A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.Cancer, , 125 (7 ) ,1124-1132 More Information

Cohen E.E.W.;Soulières D.;Le Tourneau C.;Dinis J.;Licitra L.;Ahn M.J.;Soria A.;Machiels J.P.;Mach N.;Mehra R.;Burtness B.;Zhang P.;Cheng J.;Swaby R.F.;Harrington K.J.;Acosta-Rivera M.;Adkins D.R.;Aghmesheh M.;Airoldi M.;Aleknavicius E.;Al-Farhat Y.;Algazi A.P.;Almokadem S.;Alyasova A.;Bauman J.R.;Benasso M.;Berrocal A.;Bray V.;Burtness B.A.;Caponigro F.;Castro A.;Cescon T.P.;Chan K.;Chaudhry A.;Chauffert B.;Cohen E.;Csoszi T.;De Boer J.P.;Delord J.P.;Dietz A.;Dinis J.;Dupuis C.;Digue L.;Erfan J.;Escobar Alvarez Y.;Evans M.;Fidler M.J.;Forster M.D.;Friesland S.;Ganti A.K.;Geoffrois L.;Grant C.;Gruenwald V.;Harrington K.;Hoffmann T.;Horvai G.;Inciura A.;Jang R.;Jankowska P.;Jimeno A.;Joseph M.;Juarez Ramiro A.;Karaszewska B.;Kawecki A.;Keilholz U.;Keller U.;Kim S.B.;Kocsis J.;Kotecki N.;Kozloff M.F.;Lambea J.;Landherr L.;Lantsukhay Y.;Lazarev S.A.;Lee L.W.;Lifirenko I.D.;Martincic D.;Matorin O.V.;McGrath M.;Misiukiewicz K.;Morris J.C.;Mufazalov F.F.;Niu J.;Pamoorthy Srinivasan D.;Perez Segura P.;Rauch D.;Ribeiro M.L.;Rodriguez C.;Rolland F.;Russo A.;Ruzsa A.;Sanches F.;Shin S.W.;Shtiveland M.;Soulières D.;Specenier P.;Szekanecz E.;Szota J.;van Herpen C.M.L.;Velez-Cortes H.A. (01-12-2019. ) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck.The Lancet, , 393 (10167 ) ,156-167 More Information

Morrison B.;Abu-Asab M.;Morris J.;Steel J. (01-01-2019. ) Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h.Acta virologica, , 63 (1 ) ,111-116 More Information

Abdel-Karim N.;Gaber O.;Eldessouki I.;Bahassi E.M.;Morris J. (01-01-2019. ) Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud.Asian Pacific Journal of Cancer Prevention, , 20 (12 ) ,3789-3796 More Information

Gaber O.;Eldessouki I.;Hassan R.;Magdy M.;Morris J.;Karim N. (01-01-2019. ) Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C.Asian Pacific Journal of Cancer Prevention, , 20 (8 ) ,2391-2396 More Information

Rahouma M.;Baudo M.;Yahia M.;Kamel M.;Gray K.D.;Elmously A.;Ghaly G.;Eldessouki I.;Abouarab A.;Cheriat A.N.;Karim N.A.;Mohamed A.;Morris J.;Gaudino M. (01-01-2019. ) Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm.Journal of Thoracic Disease, , 11 (2 ) ,521-534 More Information

Berzofsky J.;Terabe M.;Trepel J.;Pastan I.;Stroncek D.;Morris J.;Wood L. (12-01-2018. ) Cancer vaccine strategies: translation from mice to human clinical trials.Cancer Immunology, Immunotherapy, , 67 (12 ) ,1863-1869 More Information

Ferris R.L.;Saba N.F.;Gitlitz B.J.;Haddad R.;Sukari A.;Neupane P.;Morris J.C.;Misiukiewicz K.;Bauman J.E.;Fenton M.;Jimeno A.;Adkins D.R.;Schneider C.J.;Sacco A.G.;Shirai K.;Bowles D.W.;Gibson M.;Nwizu T.;Gottardo R.;Manjarrez K.L.;Dietsch G.N.;Kyle Bryan J.;Hershberg R.M.;Cohen E.E.W. (11-01-2018. ) Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients .JAMA Oncology, , 4 (11 ) ,1583-1588 More Information

Savona M.;Kolibaba K.;Conkling P.;Kingsley E.;Becerra C.;Morris J.;Rifkin R.;Laille E.;Kellerman A.;Ukrainskyj S.;Dong Q.;Skikne B. (10-01-2018. ) Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.American Journal of Hematology, , 93 (10 ) ,1199-1206 More Information

Rahouma M.;Kamel M.;Abouarab A.;Eldessouki I.;Nasar A.;Harrison S.;Lee B.;Shostak E.;Morris J.;Stiles B.;Altorki N.K.;Port J.L. (08-16-2018. ) Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based .ecancermedicalscience, , 12 , More Information

Morrison B.;Steel J.;Morris J. (04-26-2018. ) Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.BMC Cancer, , 18 (1 ) , More Information

Eldessouki I.;Gaber O.;Namad T.;Wang J.;Morris J.;Karim N. (01-01-2018. ) Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer .Journal of Oncology, , 2018 , More Information

Karim N.A.;Schuster J.;Eldessouki I.;Gaber O.;Namad T.;Wang J.;Xie C.;Morris J.C. (01-01-2018. ) Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.Oncotarget, , 9 (3 ) ,4102-4108 More Information

Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. (01-01-2018. ) Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in.Translational Oncology, , 11 (1 ) ,168-174 More Information

Haque S.;Morris J. (08-03-2017. ) Transforming growth factor-?: A therapeutic target for cancer.Human Vaccines and Immunotherapeutics, , 13 (8 ) ,1741-1750 More Information

Zandvakili I.;Lin Y.;Morris J.;Zheng Y. (06-08-2017. ) Rho GTPases: Anti-or pro-neoplastic targets?.Oncogene, , 36 (23 ) ,3213-3222 More Information

Wise-Draper T.;Moorthy G.;Salkeni M.;Karim N.;Thomas H.;Mercer C.;Beg M.;O’Gara S.;Olowokure O.;Fathallah H.;Kozma S.;Thomas G.;Rixe O.;Desai P.;Morris J. (06-01-2017. ) A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat.Targeted Oncology, , 12 (3 ) ,323-332 More Information

Sarantopoulos J.;Mita A.C.;He A.;Wade J.L.;Hsueh C.T.;Morris J.C.;Lockhart A.C.;Quinn D.I.;Hwang J.;Mier J.;Zhang W.;Wack C.;Yin J.;Clot P.F.;Rixe O. (02-01-2017. ) Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal.Cancer Chemotherapy and Pharmacology, , 79 (2 ) ,339-351 More Information

Sharma K.;Janik J.E.;O'Mahony D.;Stewart D.;Pittaluga S.;Stetler-Stevenson M.;Jaffe E.S.;Raffeld M.;Fleisher T.A.;Lee C.C.;Steinberg S.M.;Waldmann T.A.;Morris J.C. (01-01-2017. ) Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l.Clinical Cancer Research, , 23 (1 ) ,35-42 More Information

Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. (10-01-2016. ) immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap.Annals of Oncology, , 27 ,vi573 More Information

Janik J.E.;Morris J.C.;O'Mahony D.;Pittaluga S.;Jaffe E.S.;Redon C.E.;Bonner W.M.;Brechbiel M.W.;Paik C.H.;Whatley M.;Chen C.;Lee J.H.;Fleisher T.A.;Brown M.;White J.D.;Stewart D.M.;Fioravanti S.;Lee C.C.;Goldman C.K.;Bryant B.R.;Junghans R.P.;Carrasquillo J.A.;Worthy T.;Corcoran E.;Conlon K.C.;Waldmann T.A. (10-20-2015. ) 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o.Proceedings of the National Academy of Sciences of the United States of America, , 112 (42 ) ,13045-13050 More Information

Rixe O.;Puzanov I.;Lo Russo P.M.;Cohen R.B.;Morris J.C.;Olowokure O.O.;Yin J.Y.;Doroumian S.;Shen L.;Olszanski A.J. (08-01-2015. ) Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient.Anti-Cancer Drugs, , 26 (7 ) ,785-792 More Information

Lacouture M.;Morris J.;Lawrence D.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Berzofsky J.;Hsu F.;Guitart J. (03-22-2015. ) Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g.Cancer Immunology, Immunotherapy, , 64 (4 ) ,437-446 More Information

Van Waes C.;Bian Y.;Allen C.;Morris J.;Chen Z. (01-01-2015. ) Squamous-cell carcinoma.Molecular Oncology: Causes of Cancer and Targets for Treatment, , 686-692 More Information

Palma N.;Morris J.C.;Ali S.M.;Ross J.S.;Pal S.K. (01-01-2015. ) Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating .European Urology, , 68 (1 ) ,168-170 More Information

Wang Y.;Sui Y.;Kato S.;Hogg A.E.;Steel J.C.;Morris J.C.;Berzofsky J.A. (01-01-2015. ) Vaginal type-II mucosa is an inductive site for primary CD8+ T-cell mucosal i.Nature Communications, , 6 , More Information

Conlon K.C.;Lugli E.;Welles H.C.;Rosenberg S.A.;Fojo A.T.;Morris J.C.;Fleisher T.A.;Dubois S.P.;Perera L.P.;Stewart D.M.;Goldman C.K.;Bryant B.R.;Decker J.M.;Chen J.;Worthy T.A.;Figg W.D.;Peer C.J.;Sneller M.C.;Lane H.C.;Yovandich J.L.;Creekmore S.P.;Roederer M.;Waldmann T.A. (01-01-2015. ) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine.Journal of Clinical Oncology, , 33 (1 ) ,74-82 More Information

Berkowitz J.;Janik J.;Stewart D.;Jaffe E.;Stetler-Stevenson M.;Shih J.;Fleisher T.;Turner M.;Urquhart N.;Wharfe G.;Figg W.;Peer C.;Goldman C.;Waldmann T.;Morris J. (12-01-2014. ) Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a.Clinical Immunology, , 155 (2 ) ,176-187 More Information

Morris J.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Reiss M.;Hsu F.;Berzofsky J.;Lawrence D. (03-11-2014. ) Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon.PLoS ONE, , 9 (3 ) , More Information

Sarantopoulos J.;Mita A.C.;Wade J.L.;Morris J.C.;Rixe O.;Mita M.M.;Dedieu J.F.;Wack C.;Kassalow L.;Craig Lockhart A. (02-05-2014. ) Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat.Cancer Chemotherapy and Pharmacology, , 74 (6 ) ,1113-1124 More Information

Ramlogan-Steel C.;Steel J.;Morris J. (01-01-2014. ) Lung cancer vaccines: Current status and future prospects.Translational Lung Cancer Research, , 3 (1 ) ,46-52 More Information

Morris J.;Ramlogan-Steel C.;Yu P.;Black B.;Mannan P.;Allison J.;Waldmann T.;Steel J. (01-01-2014. ) Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer.Gene Therapy, , 21 (4 ) ,393-401 More Information

Morrison B.;Morris J.;Steel J. (09-01-2013. ) Lung cancer-initiating cells: A novel target for cancer therapy.Targeted Oncology, , 8 (3 ) ,159-172 More Information

Pang Y.;Gara S.;Achyut B.;Li Z.;Yan H.;Day C.;Weiss J.;Trinchieri G.;Morris J.;Yang L. (08-01-2013. ) TGF-? Signaling in myeloid cells is required for tumor metastasis.Cancer Discovery, , 3 (8 ) ,936-951 More Information

Waldmann T.A.;Conlon K.C.;Stewart D.M.;Worthy T.Y.A.;Janik J.E.;Fleisher T.A.;Albert P.S.;Figg W.D.;Spencer S.D.;Raffeld M.;Decker J.R.;Goldman C.K.;Bryant B.R.;Petrus M.N.;Creekmore S.P.;Morris J.C. (07-17-2013. ) Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T.Blood, , 121 (3 ) ,476-484 More Information

Morrison B.;Steel J.;Morris J. (05-01-2013. ) Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies.Future Oncology, , 9 (5 ) ,623-625 More Information

Steel J.;Di Pasquale G.;Ramlogan C.;Patel V.;Chiorini J.;Morris J. (01-01-2013. ) Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth.Molecular Therapy, , 21 (3 ) ,680-687 More Information

Chen J.;Pise-Masison C.;Shih J.;Morris J.;Janik J.;Conlon K.;Keating A.;Waldmann T. (01-01-2013. ) Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 .Blood, , 121 (11 ) ,2029-2037 More Information

Steel J.C.;Morrison B.J.;Morris J.C. (12-07-2012. ) Monoclonal antibodies for the treatment of cancer .Principles of Molecular Diagnostics and Personalized Cancer Medicine, , 580-593

Morrison B.;Steel J.;Morris J. (11-13-2012. ) Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells.PLoS ONE, , 7 (11 ) , More Information

Simone C.B.;Morris J.C.;Stewart D.M.;Urquhart N.E.;Janik J.E.;Kreitman R.J.;Lita E.;Conlon K.;Wharfe G.;Waldmann T.A.;Kaushal A. (08-30-2012. ) Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho.Blood, , 120 (9 ) ,1816-1819 More Information

Larson T.;Hu M.;Janik J.;Nussenblatt R.;Morris J.;Sen H. (08-01-2012. ) Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.Ocular Immunology and Inflammation, , 20 (4 ) ,312-314 More Information

Yu P.;Steel J.;Zhang M.;Morris J.;Waitz R.;Fasso M.;Allison J.;Waldmann T. (04-17-2012. ) Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost.Proceedings of the National Academy of Sciences of the United States of America, , 109 (16 ) ,6187-6192 More Information

Tembhare P.;Yuan C.;Morris J.;Janik J.;Filie A.;Stetler-Stevenson M. (02-01-2012. ) Flow cytometric immunophenotypic assessment of T-cell clonality by V ? repert.American Journal of Clinical Pathology, , 137 (2 ) ,220-226 More Information

Chen J.;Petrus M.;Bamford R.;Shih J.;Morris J.;Janik J.;Waldmann T. (01-05-2012. ) Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia.Blood, , 119 (1 ) ,137-143 More Information

Steel J.;Waldmann T.;Morris J. (01-01-2012. ) Interleukin-15 biology and its therapeutic implications in cancer.Trends in Pharmacological Sciences, , 33 (1 ) ,35-41 More Information

Starnes S.;Pathrose P.;Wang J.;Succop P.;Morris J.;Bridges J.;Kupert E.;Anderson M. (01-01-2012. ) Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer.Annals of Thoracic Surgery, , 93 (5 ) ,1606-1612 More Information

Vinogradova Y.;Kaplanskaya I.;Samoilova R.;Vorobiev I.;Zingerman B.;Sidorova Y.;Shklovskiy-Kordi N.;Aitova L.;Maryin D.;Morris J.;Varticovski L.;Vorobiev A. (01-01-2012. ) Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia.Clinical Medicine Insights: Blood Disorders, , 5 ,1-13 More Information

Stewart D.;Ramanathan R.;Mahanty S.;Fedorko D.;Janik J.;Morris J. (08-01-2011. ) Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma.Acta Haematologica, , 126 (2 ) ,63-67 More Information

Venkataraman G.;Berkowitz J.;Morris J.;Janik J.;Raffeld M.;Pittaluga S. (07-01-2011. ) Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.Human Pathology, , 42 (7 ) ,1042-1046 More Information

Tembhare P.;Yuan C.;Xi L.;Morris J.;Liewehr D.;Venzon D.;Janik J.;Raffeld M.;Stetler-Stevenson M. (06-01-2011. ) Flow cytometric immunophenotypic assessment of T-cell clonality by V ? repert.American Journal of Clinical Pathology, , 135 (6 ) ,890-900 More Information

Kelly R.;Lopez-Chavez A.;Citrin D.;Janik J.;Morris J. (04-06-2011. ) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.Molecular Cancer, , 10 , More Information

Ju W.;Zhang M.;Jiang J.K.;Thomas C.J.;Oh U.;Bryant B.R.;Chen J.;Sato N.;Tagaya Y.;Morris J.C.;Janik J.E.;Jacobson S.;Waldmann T.A. (02-10-2011. ) CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c.Blood, , 117 (6 ) ,1938-1946 More Information

Martiniova L.;Perera S.M.;Brouwers F.M.;Alesci S.;Abu-Asab M.;Marvelle A.F.;Kiesewetter D.O.;Thomasson D.;Morris J.C.;Kvetnansky R.;Tischler A.S.;Reynolds J.C.;Fojo A.T.;Pacak K. (02-01-2011. ) Increased uptake of [123I]meta-iodobenzylguanidine, [ 18.Endocrine-Related Cancer, , 18 (1 ) ,143-157 More Information

Chen J.;Petrus M.;Bryant B.;Nguyen V.;Goldman C.;Bamford R.;Morris J.;Janik J.;Waldmann T. (12-23-2010. ) Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad.Blood, , 116 (26 ) ,5948-5956 More Information

Yu P.;Steel J.;Zhang M.;Morris J.;Waldmann T. (12-15-2010. ) Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m.Clinical Cancer Research, , 16 (24 ) ,6019-6028 More Information

Shurin M.;Gregory M.;Morris J.;Malyguine A. (11-01-2010. ) Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow?.Expert Opinion on Biological Therapy, , 10 (11 ) ,1539-1553 More Information

Van Waes C.;Allen C.;Citrin D.;Gius D.;Colevas A.;Harold N.;Rudy S.;Nottingham L.;Muir C.;Chen Z.;Singh A.;Dancey J.;Morris J. (06-01-2010. ) Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca.International Journal of Radiation Oncology Biology Physics, , 77 (2 ) ,447-454 More Information

Moriyama B.;Henning S.;Childs R.;Holland S.;Anderson V.;Morris J.;Wilson W.;Drusano G.;Walsh T. (05-01-2010. ) High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi.Annals of Pharmacotherapy, , 44 (5 ) ,929-935 More Information

Shao H.;Yuan C.;Xi L.;Raffeld M.;Morris J.;Janik J.;Stetler-Stevenson M. (04-01-2010. ) Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.American Journal of Clinical Pathology, , 133 (4 ) ,592-601 More Information

Kelly R.;Morris J. (03-01-2010. ) Transforming growth factor-beta: A target for cancer therapy.Journal of Immunotoxicology, , 7 (1 ) ,15-26 More Information

Steel J.;Ramlogan C.;Yu P.;Sakai Y.;Forni G.;Waldmann T.;Morris J. (02-01-2010. ) Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through .Cancer Research, , 70 (3 ) ,1072-1081 More Information

Janik J.;Morris J. (12-17-2009. ) Survivin(g) adult T-cell leukemia/lymphoma .ONCOLOGY, , 23 (14 ) ,

Morris J.;Waldmann T. (12-01-2009. ) Antibody-based therapy of leukaemia.Expert Reviews in Molecular Medicine, , 11 , More Information

Morrison B.J.;Steel J.C.;Gregory M.;Morris J.C.;Malyguine A.M. (12-01-2009. ) Genetically modified dendritic cells in cancer immunotherapy.Dendritic Cells in Cancer, , 347-363 More Information

Pise-Masison C.;Radonovich M.;Dohoney K.;Morris J.;O'Mahony D.;Lee M.;Trepel J.;Waldmann T.;Janik J.;Brady J. (11-17-2009. ) Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF.Blood, , 113 (17 ) ,4016-4026 More Information

Janik J.;O'Mahony D.;Waldmann T.;Morris J. (09-09-2009. ) Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant .Haematologica Meeting Reports, , 3 (1 ) ,61-68

Citrin D.;Mansueti J.;Likhacheva A.;Sciuto L.;Albert P.;Rudy S.;Cooley-Zgela T.;Cotrim A.;Solomon B.;Colevas A.;Russo A.;Morris J.;Herscher L.;Smith S.;Van Waes C. (07-15-2009. ) Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head-.International Journal of Radiation Oncology Biology Physics, , 74 (4 ) ,1040-1046 More Information

Jiang L.;Yuan C.;Hubacheck J.;Janik J.;Wilson W.;Morris J.;Jasper G.;Stetler-Stevenson M. (04-01-2009. ) Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the.British Journal of Haematology, , 145 (2 ) ,173-179 More Information

Pernas F.G.;Allen C.T.;Winters M.E.;Yan B.;Friedman J.;Dabir B.;Saigal K.;Mundinger G.S.;Xu X.;Morris J.C.;Calvo K.R.;Van Waes C.;Chen Z. (04-01-2009. ) Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to .Clinical Cancer Research, , 15 (7 ) ,2361-2372 More Information

O'Mahony D.;Morris J.;Stetler-Stevenson M.;Matthews H.;Brown M.;Fleisher T.;Pittaluga S.;Raffeld M.;Albert P.;Reitsma D.;Kaucic K.;Hammershaimb L.;Waldmann T.;Janik J. (04-01-2009. ) EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, .Clinical Cancer Research, , 15 (7 ) ,2514-2522 More Information

Martiniova L.;Lai E.;Elkahloun A.;Abu-Asab M.;Wickremasinghe A.;Solis D.;Perera S.;Huynh T.;Lubensky I.;Tischler A.;Kvetnansky R.;Alesci S.;Morris J.;Pacak K. (03-01-2009. ) Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g.Clinical and Experimental Metastasis, , 26 (3 ) ,239-250 More Information

Lai E.;Joshi B.;Martiniova L.;Dogra R.;Fujisawa T.;Leland P.;De Krijger R.;Lubensky I.;Elkahloun A.;Morris J.;Puri R.;Pacak K. (01-01-2009. ) Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t.Journal of Clinical Endocrinology and Metabolism, , 94 (8 ) ,2952-2957 More Information

Sharp H.;Morris J.;Van Waes C.;Gius D.;Cooley-Zgela T.;Singh A. (12-01-2008. ) High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea.American Journal of Clinical Oncology: Cancer Clinical Trials, , 31 (6 ) ,557-560 More Information

Eisenhofer G.;Huynh T.;Elkahloun A.;Morris J.;Bratslavsky G.;Linehan W.;Zhuang Z.;Balgley B.;Lee C.;Mannelli M.;Lenders J.;Bornstein S.;Pacak K. (11-01-2008. ) Differential expression of the regulated catecholamine secretory pathway in different hereditary for.American Journal of Physiology - Endocrinology and Metabolism, , 295 (5 ) , More Information

Chen J.;Petrus M.;Bryant B.R.;Nguyen V.P.;Stamer M.;Goldman C.K.;Bamford R.;Morris J.C.;Janik J.E.;Waldmann T.A. (05-15-2008. ) Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T.Blood, , 111 (10 ) ,5163-5172 More Information

Morris J.;Waldmann T.;Janik J. (04-01-2008. ) Receptor-directed therapy of T-cell leukemias and lymphomas.Journal of Immunotoxicology, , 5 (2 ) ,235-248 More Information

Ohta S.;Lai E.W.;Morris J.C.;Pang A.L.Y.;Watanabe M.;Yazawa H.;Zhang R.;Green J.E.;Chan W.Y.;Sirajuddin P.;Taniguchi S.;Powers J.F.;Tischler A.S.;Pacak K. (04-01-2008. ) Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p.Molecular Carcinogenesis, , 47 (4 ) ,245-251 More Information

Jong M.;Terabe M.;Steel J.;Forni G.;Sakai Y.;Morris J.;Berzofsky J. (03-15-2008. ) Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin.Cancer Research, , 68 (6 ) ,1979-1987 More Information

O'Mahony D.;Debnath I.;Janik J.;Aisner D.;Jaffe E.;Waldmann T.;Morris J. (03-01-2008. ) Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly.Leukemia and Lymphoma, , 49 (3 ) ,439-446 More Information

Steel J.;Morrison B.;Mannan P.;Abu-Asab M.;Wildner O.;Miles B.;Yim K.;Ramanan V.;Prince G.;Morris J. (12-05-2007. ) Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly.Virology, , 369 (1 ) ,131-142 More Information

Alesci S.;Abu-Asab M.;Perera S.;Tsokos M.;Morris J.;Pacak K. (12-01-2007. ) Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy.NeuroImmunoModulation, , 14 (5 ) ,221-223 More Information

Alesci S.;Perera S.;Lai E.;Kukura C.;Abu-Asab M.;Tsokos M.;Morris J.;Pacak K. (08-01-2007. ) Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin.Endocrinology, , 148 (8 ) ,3900-3907 More Information

Morris J.;Janik J. (06-01-2007. ) Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning.Leukemia and Lymphoma, , 48 (6 ) ,1067-1069 More Information

Steel J.;Cavanagh H.;Burton M.;Abu-Asab M.;Tsokos M.;Morris J.;Kalle W. (04-01-2007. ) Increased tumor localization and reduced immune response to adenoviral vector formulated with the li.European Journal of Pharmaceutical Sciences, , 30 (5 ) ,398-405 More Information

Burke J.;Morris J. (03-01-2007. ) Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression.Molecular Therapy, , 15 (3 ) ,552-559 More Information

O'Mahony D.;Morris J.;Quinn C.;Gao W.;Wilson W.;Gause B.;Pittaluga S.;Neelapu S.;Brown M.;Fleisher T.;Gulley J.;Schlom J.;Nussenblatt R.;Albert P.;Davis T.;Lowy I.;Petrus M.;Waldmann T.;Janik J. (02-01-2007. ) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.Clinical Cancer Research, , 13 (3 ) ,958-964 More Information

Ohta S.;Lai E.W.;Morris J.C.;Bakan D.A.;Klaunberg B.;Cleary S.;Powers J.F.;Tischler A.S.;Abu-Asab M.;Schimel D.;Pacak K. (11-01-2006. ) MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice.International Journal of Cancer, , 119 (9 ) ,2236-2241 More Information

Waldmann T.;Morris J. (05-29-2006. ) Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy.Advances in Immunology, , 90 ,83-131 More Information

Morris J.;Janik J.;White J.;Fleisher T.;Brown M.;Tsudo M.;Goldman C.;Bryant B.;Petrus M.;Top L.;Lee C.;Gao W.;Waldmann T. (01-10-2006. ) Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel.Proceedings of the National Academy of Sciences of the United States of America, , 103 (2 ) ,401-406 More Information

Van Waes C.;Chang A.A.;Lebowitz P.F.;Druzgal C.H.;Chen Z.;Elsayed Y.A.;Sunwoo J.B.;Rudy S.F.;Morris J.C.;Mitchell J.B.;Camphausen K.;Gius D.;Adams J.;Sausville E.A.;Conley B.A. (12-01-2005. ) Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b.International Journal of Radiation Oncology Biology Physics, , 63 (5 ) ,1400-1412 More Information

Druzgal C.;Chen Z.;Yeh N.;Thomas G.;Ondrey F.;Duffey D.;Vilela R.;Ende K.;McCullagh L.;Rudy S.;Muir C.;Herscher L.;Morris J.;Albert P.;Van Waes C. (09-01-2005. ) A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti.Head and Neck, , 27 (9 ) ,771-784 More Information

Park J.;Terabe M.;Sakai Y.;Munasinghe J.;Forni G.;Morris J.;Berzofsky J. (04-01-2005. ) Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine prote.Journal of Immunology, , 174 (7 ) ,4228-4236 More Information

Janik J.;Morris J.;Pittaluga S.;McDonald K.;Raffeld M.;Jaffe E.;Grant N.;Gutierrez M.;Waldmann T.;Wilson W. (11-15-2004. ) Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.Blood, , 104 (10 ) ,3355-3357 More Information

Sakai Y.;Morrison B.;Burke J.;Park J.;Terabe M.;Janik J.;Forni G.;Berzofsky J.;Morris J. (11-01-2004. ) Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev.Cancer Research, , 64 (21 ) ,8022-8028 More Information

Berzofsky J.;Ahlers J.;Janik J.;Morris J.;Oh S.;Terabe M.;Belyakov I. (08-01-2004. ) Progress on new vaccine strategies against chronic viral infections.Journal of Clinical Investigation, , 114 (4 ) ,450-462 More Information

Wolkersdörfer G.W.;Morris J.C.;Ehninger G.;Ramsey W.J. (06-01-2004. ) Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.Journal of Gene Medicine, , 6 (6 ) ,652-662 More Information

Okada T.;Caplen N.;Ramsey W.;Onodera M.;Shimazaki K.;Nomoto T.;Ajalli R.;Wildner O.;Morris J.;Kume A.;Hamada H.;Blaese R.;Ozawa K. (03-01-2004. ) In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce.Journal of Gene Medicine, , 6 (3 ) ,288-299 More Information

Lee S.S.;Robinson M.R.;Morris J.C.;Mirtsching B.C.;Shen D.F.;Chan C.C. (01-01-2004. ) Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit.Survey of Ophthalmology, , 49 (5 ) ,525-536 More Information

Berzofsky J.;Terabe M.;Oh S.;Belyakov I.;Ahlers J.;Janik J.;Morris J. (01-01-2004. ) Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Journal of Clinical Investigation, , 113 (11 ) ,1515-1525 More Information

Morris J. (06-01-2003. ) Cancer gene therapy: Lessons learned from experiences with chemotherapy.Molecular Therapy, , 7 (6 ) ,717-719 More Information

Wildner O.;Morris J. (01-01-2002. ) Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: .Human Gene Therapy, , 13 (1 ) ,101-112 More Information

Lei J.Y.;Wang Y.;Jaffe E.S.;Turner M.L.;Raffeld M.;Sorbara L.;Morris J.;Holland S.M.;Duray P.H. (12-01-2000. ) Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim.American Journal of Dermatopathology, , 22 (6 ) ,524-529 More Information

Morris J.;Waldmann T. (11-20-2000. ) Advances in interleukin 2 receptor targeted treatment .Annals of the Rheumatic Diseases, , 59 (SUPPL. 1 ) ,

Wildner O.;Morris J. (08-31-2000. ) The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi .Cancer Research, , 60 (15 ) ,4167-4174

Morris J.;Ramsey W.;Wildner O.;Muslow H.;Aguilar-Cordova E.;Blaese R. (02-10-2000. ) A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi.Human Gene Therapy, , 11 (3 ) ,487-503 More Information

Wildner O.;Morris J. (01-01-2000. ) Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.Journal of Gene Medicine, , 2 (5 ) ,353-360 More Information

Morris J.;Wildner O. (01-01-2000. ) Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk.Molecular Therapy, , 1 (1 ) ,56-62 More Information

Wildner O.;Blaese R.;Morris J. (11-01-1999. ) Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase.Human Gene Therapy, , 10 (16 ) ,2679-2687 More Information

Wildner O.;Blaese R.;Morris J. (01-16-1999. ) Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru .Cancer Research, , 59 (2 ) ,410-413

Wildner O.;Morris J.;Vahanian N.;Ford H.;Ramsey W.;Blaese R. (01-01-1999. ) Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of .Gene Therapy, , 6 (1 ) ,57-62 More Information

Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C (2019. ) Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.Oxford medical case reports, , 2019 (11 ) ,461-463 More Information

Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario (2019. ) Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials.Journal of thoracic disease, , 11 (2 ) ,521-534 More Information

Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla (2018. ) Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience.Journal of oncology, , 2018 ,9761826 More Information

Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L (2018. ) Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis.Ecancermedicalscience, , 12 ,859 More Information

Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa (2018. ) Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.Translational oncology, , 11 (1 ) ,168-174 More Information

Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C (2018. ) Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.Oncotarget, , 9 (3 ) ,4102-4108 More Information

Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D (2017. ) American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.Thyroid : official journal of the American Thyroid Association, , 27 (4 ) ,481-483 More Information

Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C (2016. ) Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.Journal of the National Comprehensive Cancer Network : JNCCN, , 14 (10 ) ,1203-1207 More Information

Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum.Journal of investigative medicine high impact case reports, , 2 (2 ) ,2324709614532798 More Information

Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C (2014. ) Lung cancer vaccines: current status and future prospects.Translational lung cancer research, , 3 (1 ) ,46-52 More Information

Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A (2013. ) Mucoepidermoid carcinoma of the lung: a case report and literature review.Case reports in oncological medicine, , 2013 ,625243 More Information

Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall (2012. ) Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.The Annals of thoracic surgery, , 93 (5 ) ,1606-12 More Information

Ghose A.;Morris J.C.;Breneman J.C.;Essell J.;Wang J.;Benzaquen S. (01-01-2014. ) Medulloblastoma in an adult with late extraneural metastases to the mediastinum.Journal of Investigative Medicine High Impact Case Reports, , 2 (2 ) , More Information

Presentations

Invited Presentations

John C. Morris, MD (07-24-2009. ) Transforming growth factor-betha: A target for cancer therapy .University of Cincinnati, Cincinnati, OH.

John C. Morris, MD (05-20-2009. ) Transforming growth factor-beta: A target for cancer immunotherapy .First International Conference on Cancer Immunotherapy and Immunomonitoring, Kiev, Ukraine.

John C. Morris, MD (11-15-2008. ) SynCure Cancer Research Foundation:Living with Cancer from Diagnosis to Survivor: "Advances in the Diagnosis and Treatment of Solid Tumor Cancers" .Grand Summit Hotel, Summit, NJ.

John C. Morris, MD (09-11-2008. ) Cancer Immunology and Immunotherapy: Realizign the Promise, Immune Modulatory Molecules .Bethesda, MD.

John C. Morris, MD (05-27-2008. ) Institut de Recherches Clinique de Montreal (IRCM), Training program in Cancer Research Workshop .Montreal, Canada.

John C. Morris, MD (12-06-2007. ) Immunodiagnostics & Immunomonitoring: From Research to Clinic .Washington, DC.

John C. Morris, MD (10-19-2007. ) "Receptor-directed therapy of T-cell leukemia and lymphoma" .Washington Hospital Center, Washington, DC.

John C. Morris, MD (09-10-2007. ) Session Chairman: Immune Mediated Diseases: From Theory to Therapy .Moscow, Russia.

Honors and Awards

2009 10- Year Federal Service Recognition Certificate

2009 Federal Technology Transfer Award

2008 Federal Technology Transfer Award

2008 NCI Best Case Series Office of Cancer Complementary and Alternative Medicine Nominal Award

2003 NCI Outstanding Mentor Award Nominee

1999 NHGRI Scientific Retreat Poster Presentation Award

1999 NIH "Bench to Bedside" Grant Award "Evaluation of an E1b 55-kD Expressing Replicating Adenovirus Expressing HSV-tk (Ad.OW34) in Advanced Squamous Cell Carcinoma of the Head and Neck"

1994 Solomon R. Berson Teaching Award 1st Runner-up

1992 Mount Sinai Hospital's "Physician of the Year" Award Nominee

1991 One of "The Best Physicians in New York" Listed in New York Magazine

Keywords

Hematology/Oncology, Cancer, Oncology, Head & Neck Cancer, Lung Cancer

Contact Information

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2158
Fax: 513-558-2124
john.morris2@uc.edu